This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3D Systems Plunges 20% in a Month: Buy, Sell or Hold the Stock?
by Zacks Equity Research
DDD's printing potential bodes well. However, declining revenues and soft demand due to macroeconomic challenges cloud its outlook.
3D Systems Stock Falls as Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
DDD's Q3 results suffer from reduced printer sales, led by macroeconomic challenges impacting hardware demand.
Digi International (DGII) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Digi International (DGII) delivered earnings and revenue surprises of 4% and 0.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for October 22nd
by Zacks Equity Research
DDD, FLWS and ALLY have been added to the Zacks Rank #5 (Strong Sell) List on October 22, 2024.
DDD Boosts Dental 3D Printing: How Should Investors Play the Stock?
by Zacks Equity Research
3D Systems gains FDA clearance for its advanced jetted denture solution, enhancing durability and efficiency in dental labs for an improved patient experience.
3D Systems Down 64% YTD: How Should Investors Play the Stock?
by Zacks Equity Research
DDD does not offer a good investment opportunity due to challenging macroeconomic conditions and stiff competition.
3D Systems (DDD) Q1 Earnings Miss Estimates, Revenues Down Y/Y
by Zacks Equity Research
3D Systems (DDD) first-quarter 2024 top-line growth suffers from challenging macroeconomic conditions.
Iridex (IRIX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Iridex (IRIX) delivered earnings and revenue surprises of -33.33% and 1.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
3D Systems (DDD) Expands Portfolio With Precision Partnership
by Zacks Equity Research
3D Systems (DDD) and Precision Resource partner to transform additive manufacturing with advanced DMP technology, enhancing precision and performance in critical industries.
Stratasys (SSYS) Tests 3D Printed Models in Orthopedic Oncology
by Zacks Equity Research
Stratasys (SSYS) and Ricoh co-sponsor a clinical study comparing the efficacy of 3D-printed models to traditional CT or MRI scanning for bone tumor excision planning.